Otwarty dostęp

Anti-inflammatory activity of novel natural plant extracts composition—LevidorTM

Monika Kuczyńska
Monika Kuczyńska
, 
Paulina Kasprzyk
Paulina Kasprzyk
, 
Magdalena Leszczyńska-Wiloch
Magdalena Leszczyńska-Wiloch
, 
Joanna Bidzińska
Joanna Bidzińska
, 
Marcin Martyniak
Marcin Martyniak
, 
Alicja Wilandt
Alicja Wilandt
 oraz 
Krzysztof Lemke
Krzysztof Lemke
   | 22 maj 2023
Postępy Higieny i Medycyny Doświadczalnej's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Article Category: Original Study
Data publikacji: 22 maj 2023
Zakres stron: 49 - 58
Otrzymano: 14 paź 2022
Przyjęty: 21 mar 2023
DOI: https://doi.org/10.2478/ahem-2023-0008
Słowa kluczowe
© 2023 Monika Kuczyńska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1

The effect of LevidorTM extract on pro-inflammatory markers (IL-6, TNF-α) induced by LPS in the RAW267.7 cells. All results are given as means ± SD of three independent determinations. Negative control (C−) refers to cells treated with solvent, while positive control (C+) relates to cells treated with inflammatory inducer only. Significantly different values are marked as (*) p ≤ 0.05
The effect of LevidorTM extract on pro-inflammatory markers (IL-6, TNF-α) induced by LPS in the RAW267.7 cells. All results are given as means ± SD of three independent determinations. Negative control (C−) refers to cells treated with solvent, while positive control (C+) relates to cells treated with inflammatory inducer only. Significantly different values are marked as (*) p ≤ 0.05

Fig. 2

Changes in COX-1 (A) and COX-2 (B) gene expression in the U937 cells after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2,5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 2, 4, 6, and 16 h. Results are presented as fold changes in the expression of investigated genes. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer. Significantly different values are marked as (*) p ≤ 0.05. The results are calculated based on three independent experiments
Changes in COX-1 (A) and COX-2 (B) gene expression in the U937 cells after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2,5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 2, 4, 6, and 16 h. Results are presented as fold changes in the expression of investigated genes. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer. Significantly different values are marked as (*) p ≤ 0.05. The results are calculated based on three independent experiments

Fig. 3

Western blot analysis of the modulation of COX-1 and COX-2 protein abundance in the U937 after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2.5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 24 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)
Western blot analysis of the modulation of COX-1 and COX-2 protein abundance in the U937 after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2.5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 24 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)

Fig. 4

Visualisation of COX-1 and COX-2 protein in the U937 cells after 24 h pre-treatment with PMA (10 ng/mL), followed by 24 h of incubation without treatment, 4 h treatment with 10, 25, and 50 μg/mL of LevidorTM as well as TNF-α addition (100 ng/mL) for 20 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)
Visualisation of COX-1 and COX-2 protein in the U937 cells after 24 h pre-treatment with PMA (10 ng/mL), followed by 24 h of incubation without treatment, 4 h treatment with 10, 25, and 50 μg/mL of LevidorTM as well as TNF-α addition (100 ng/mL) for 20 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)

Forward and reverse sequences of applied primers

Gene Forward Reverse
GAPDH 5′-AACGACCCCTTCATT-GAC-3′ 5′-TCCACGACATACTCAG-CA-3′
COX-1 5′-TCTCAGGCTA-CACCCTAGACCA-3′ 5′-ATCGGGGTAGTCCGAG-TAACGT-3′
COX-2 5′-CAGCACTTCACGCAT-CAGTT-3′ 5′-CGCAGTTTACGCTGTC-TAGC-3′

Values of IC50 obtained by MTT test

Cell line IC50 [μg/mL]
RAW264.37 not cytotoxic at concentration range tested
PC-12 193.1
eISSN:
1732-2693
Język:
Angielski
Częstotliwość wydawania:
Volume Open
Dziedziny czasopisma:
Life Sciences, Molecular Biology, Microbiology and Virology, Medicine, Basic Medical Science, Immunology
Kanał RSS czasopisma